SCHEMBL4011041

SCHEMBL4011041

O=S(=O)(Nc1ccc2[nH]nc(O)c2c1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.53
LNPEP Q9UIQ6 1/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
HTR6 P50406 3/20 0.47
KIT P10721 1/20 0.47
PKM P14618 1/20 0.46
PKLR P30613 1/20 0.46
MAPT P10636 3/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
PGR P06401 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007831 0.95 MAP2K4 (0.55) MAP2K4LNPEPKMT2AMEN1CYP1A2
SCHEMBL1461661 0.88 MAP2K4 (0.52) MAP2K4LNPEPKMT2AMEN1CYP1A2
SCHEMBL27676127 0.86 JAK2 (0.54) MAP2K4LNPEPKMT2AMEN1CYP1A2
SCHEMBL1460607 0.85 KIT (0.52) MAP2K4LNPEPKMT2AMEN1CYP1A2
SCHEMBL4015269 0.85 MAP2K4 (0.50) MAP2K4LNPEPKMT2AMEN1CYP1A2
SCHEMBL4010483 0.84 CHEK2 (0.52) MAP2K4LNPEPKMT2AMEN1CYP1A2
SCHEMBL26715246 0.83 ALDH1A1 (0.50) MAP2K4KMT2AMEN1HTR6KIT
SCHEMBL4007929 0.82 MAP2K4 (0.54) MAP2K4LNPEPKMT2AMEN1CYP1A2
SCHEMBL1461652 0.82 MAP2K4 (0.60) MAP2K4LNPEPKITPGR
SCHEMBL4009076 0.82 MAP2K4 (0.48) MAP2K4LNPEPKMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 US disclosed
CN-100369899-C Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2008-02-20 CN disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAP2K4 340/4885LNPEP 4312/4885KMT2A 1089/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAP2K4 328/4885LNPEP 4451/4885KMT2A 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.